Methotrexate Accord

Methotrexate, the active ingredient in Methotrexate Accord, is an antimetabolite (folate antagonist) presented as a subcutaneous formulation for subcutaneous use. It treats rheumatoid arthritis, psoriasis, and certain malignancies such as acute lymphoblastic leukemia in adult and pediatric patients.

GNH USA supplies Methotrexate Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used in several disease categories, primarily as a disease‑modifying antirheumatic drug and an antineoplastic agent. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and decreases plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation and induces remission. - Other responsive malignancies: provides antineoplastic activity in cancers that are sensitive to folate antagonism.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Mouth sores (stomatitis) - Fatigue or weakness - Mild skin rash

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Severe liver toxicity or hepatitis - Pulmonary fibrosis or interstitial pneumonitis - Acute renal failure

When using Methotrexate Accord, several precautions should be observed to minimize risk. - Liver monitoring: perform baseline and periodic liver function tests. - Renal monitoring: assess kidney function before and during therapy. - Hematologic monitoring: obtain regular complete blood counts. - Pregnancy avoidance: do not use in pregnant or breastfeeding women unless clearly indicated. - Infection risk: screen for active infections and avoid live vaccines during treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate can interact with other medicines, affecting its safety and effectiveness.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen, naproxen): increase methotrexate toxicity. - Other folate antagonists (e.g., trimethoprim): additive inhibition of folate metabolism.

Moderate Interactions (Monitor Closely): - Penicillins (e.g., amoxicillin): may raise methotrexate plasma levels. - Proton pump inhibitors (e.g., omeprazole): can alter methotrexate clearance. - Live vaccines (e.g., measles‑mumps‑rubella): heightened risk of infection.